Nele Assmann

Nele Assmann


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2024 in Psychotherapy and Psychosomatics
Verified
Journal Article
Open access
PDF file
NANele Assmann
Nele Assmann
ASAnja Schaich
Anja Schaich
AAArnoud Arntz
Arnoud Arntz
TWTill Wagner
Till Wagner
PHPhilipp Herzog
Philipp Herzog
EFEva Fassbinder
Eva Fassbinder
Introduction: In the treatment of borderline personality disorder (BPD), there is empirical support for both dialectical behavior therapy (DBT) and schema therapy (ST); these treatments have never been compared directly. This study examines whether either of them is more effective than the other in treating patients with BPD. Methods: In this randomized, parallel-group, rater-blind clinical trial, outpatients aged between 18 and 65 years with a primary diagnosis of BPD were recruited in a tertiary outpatient treatment center (Lübeck, Germany). Participants were randomized to DBT or ST with one individual and one group session per week over 1.5 years. The primary outcome was the BPD symptom severity assessed with the mean score of the Borderline Personality Disorder Severity Index at 1-year naturalistic follow-up. Results: Between November 26, 2014, and December 14, 2018, we enrolled 164 patients (mean age = 33.7 [SD = 10.61] years). Of these, 81 (49.4%) were treated with ST and 83 (50.6%) with DBT, overall, 130 (79.3%) were female. Intention-to-treat analysis with generalized linear mixed models did not show a significant difference at 1-year naturalistic follow-up between DBT and ST for the BPDSI total score (mean difference 3.32 [95% CI: –0.58–7.22], p = 0.094, d = −24 [–0.69; 0.20]) with lower scores for DBT. Pre-to-follow-up effect sizes were large in both groups (DBT: d = 2.45 [1.88–3.02], ST: d = 1.78 [1.26–2.29]). Conclusion: Patients in both treatment groups showed substantial improvements indicating that even severely affected patients with BPD and various comorbid disorders can be treated successfully with DBT and ST. An additional non-inferiority trial is needed to show if both treatments are equally effective. The trial was retrospectively registered on the German Clinical Trials Register, DRKS00011534 without protocol changes.

17 December 2018 in JMIR Mental Health
Verified
Journal Article
Open access
GJGitta Anne Jacob
Gitta Anne Jacob
AHAndrea Hauer
Andrea Hauer
SKSandra Köhne
Sandra Köhne
NANele Assmann
Nele Assmann
ASAnja Schaich
Anja Schaich
EFEva Fassbinder
Eva Fassbinder
Background: Electronic health (eHealth) programs have been found to be effective in treating many psychological conditions. However, regarding borderline personality disorder (BPD), only a few eHealth programs have been tested, involving small interventions based on the dialectical behavior therapy treatment approach. We investigated priovi, a program based on the schema therapy (ST) approach. priovi is considerably more comprehensive than prior programs, offering broad psychoeducation content and many therapeutic exercises. Objective: We tested the acceptability and feasibility of priovi in 14 patients with BPD as an add-on to individual face-to-face ST. Methods: Patients received weekly individual ST and used priovi over a period of 12 months. We assessed BPD symptom severity using self-reported and interview-based measures. Qualitative interviews were conducted with both patients and therapists to assess their experiences with priovi. Results: BPD symptoms improved significantly (Cohen d=1.0). Overall, qualitative data showed that priovi was positively received by both patients and therapists. Some exercises provoked mild anxiety; however, no serious threat to safety was detected. Conclusions: priovi is a potentially helpful and safe tool that could support individual ST. It needs to be further tested in a randomized controlled study. Trial Registration: German Clinical Trials Register DRKS00011538; https://www.drks.de/drks_web/navigate.do? navigationId=trial.HTML&TRIAL_ID=DRKS00011538 (Archived by WebCite at http://www.webcitation.org/74jb0AgV8)

10 September 2018 in Depression and Anxiety
Verified
Journal Article
Closed access
PDF file
NANele Assmann
Nele Assmann
ESElisabeth Schramm
Elisabeth Schramm
LKLevente Kriston
Levente Kriston
MHMartin Hautzinger
Martin Hautzinger
MHMartin Härter
Martin Härter
JKJan Philipp Klein
Jan Philipp Klein

1 January 2021 in European Journal of Psychotraumatology
Verified
Journal Article
Open access
ASAnja Schaich
Anja Schaich
NANele Assmann
Nele Assmann
SKSandra Köhne
Sandra Köhne
DADaniel Alvarez-Fischer
Daniel Alvarez-Fischer
SBStefan Borgwardt
Stefan Borgwardt
EFEva Faßbinder
Eva Faßbinder
Background: Childhood maltreatment and difficulties in emotion regulation are common in patients with Borderline Personality Disorder (BPD) and Depressive Disorders (DD). Objective: This study examines differences between patients with BPD and patients with DD, regarding childhood maltreatment and difficulties in emotion regulation as well as the mediating effect of different aspects of emotion regulation deficits on the association between childhood maltreatment and BPD-symptoms. Method: A total of 305 participants, 177 with BPD and 128 with DD completed an assessment including the Childhood Trauma Questionnaire (CTQ), the Emotion Regulation Scale (DERS), the Brief Symptom Inventory (BSI), and the Structured Clinical Interview for DSM-IV (SCID). Data was analyzed using multiple analyses of variances and mediation analyses. Results: Patients with BPD reported more childhood maltreatment and more difficulties in emotion regulation than patients with DD. When general symptom severity, age, and gender were included in the analysis as covariates only group differences regarding ‘impulse control difficulties’ (F(1,299) = 38.97, p < .001, ηp2 = .115), ‘limited access to emotion regulation strategies’ (F(1,299) = 4.66, p = .032, ηp2 = .015), and ‘lack of emotional clarity’ (F(1,299) = 9.38, p = .002, ηp2 = .030) remained statistically significant. A mediation analysis, including above-mentioned covariates, indicated an association between emotional abuse and BPD-symptoms, which was mediated by difficulties in emotion regulation (indirect effect B = .012, 95% CI [.001; .031], R2 = .429). Subscale analyses revealed ‘impulse control difficulties’ as the aspect of difficulties in emotion regulation that has the greatest impact on this association (B = .021, 95% CI [.003; .045]). Conclusions: Patients with BPD display more childhood maltreatment and difficulties in emotion regulation than patients with DD. Difficulties in emotion regulation, especially difficulties in impulse control, seem to play an important role in the association between childhood emotional abuse and BPD-symptoms.

15 April 2025 in The Lancet Psychiatry
Verified
Journal Article
Open access
NANele Assmann
Nele Assmann
GJGitta Jacob
Gitta Jacob
ASAnja Schaich
Anja Schaich
TBThomas Berger
Thomas Berger
TZTristan Zindler
Tristan Zindler
JKJan Philipp Klein
Jan Philipp Klein
Fewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we tested the effectiveness and safety of priovi, a digital therapeutic for BPD. We conducted a pragmatic, assessor-blind, parallel-group, randomised controlled trial, recruiting patients with BPD, according to DSM-5 classification, of at least moderate severity on the 23-item Borderline Symptom List (BSL-23) via online advertisements in Germany. Patients were aged 18 years or older, agreed on an emergency plan for suicidal crises, and gave informed consent to participate. Patients were excluded if they had a primary diagnosis of a substance use disorder or a diagnosis of a psychotic disorder. Simple computerised coin-toss randomisation (1:1) without stratification was used to assign patients to either the unguided digital therapeutic based on schema therapy together with treatment as usual (TAU; intervention group) or TAU alone (control group) and study investigators were masked to group assignment until after the analysis of the primary outcome and main safety outcome. All patients could use any form of usual care. The control group received freely available BPD-specific self-help material. The primary outcome was the time by treatment interaction in the intention-to-treat sample at 3 months measured by BSL-23 score. Safety was established via the number of serious adverse events (ie, suicide attempts, other life-threatening events, and hospitalisation), assessed via online questionnaire. Individuals with BPD were involved in the development of the digital therapeutic, but not in the design of this study. The trial was registered on German Clinical Trials Register (DRKS00028888) and is completed. Between May 3 and Oct 20, 2022, 1766 patients were screened for eligibility and 580 patients (520 [90%] women, 47 [8%] men, and 13 [2%] gender diverse) were randomly assigned to the intervention group (n=302) and control group (n=278). Ethnicity data were not recorded. At the primary timepoint of 3 months, 35 (12%) patients dropped out of the intervention group and 15 (5%) of the control group. The median age of patients was 29 years (IQR 24-37). Intention-to-treat analysis with linear mixed models showed a significant time by treatment interaction (p=0·0005) at 3 months in favour of the intervention group (d=0·24 [95% CI 0·07-0·42]). Regarding safety, there were significantly fewer suicide attempts in the intervention group (n=7) than in the control group (n=21; incidence rate ratio 0·34 [95% CI 0·14-0·79]; p=0·0081) and there were no differences regarding other serious adverse events. This trial provides tentative evidence of the effectiveness and absence of safety concerns of the digital therapeutic, priovi, in the treatment of individuals with BPD. GAIA.

20 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NANele Assmann
Nele Assmann
EFEva Fassbinder
Eva Fassbinder
ASAnja Schaich
Anja Schaich
CLChristopher W. Lee
Christopher W. Lee
KHKatrina Boterhoven de Haan
Katrina Boterhoven de Haan
AAArnoud Arntz
Arnoud Arntz
Patients with posttraumatic stress disorder (PTSD) frequently have comorbid diagnoses such as major depressive disorder (MDD) and anxiety disorders (AD). Studies into the impact of these comorbidities on the outcome of PTSD treatment have yielded mixed results. The different treatments investigated in these studies might explain the varied outcome. The purpose of this study was to examine the impact of these comorbidities on the outcome of two specific PTSD treatments. MDD and AD were analyzed as predictors and moderators in a trial comparing 12 sessions of either eye movement desensitization and reprocessing (EMDR) or imagery rescripting (IR) in 155 adult patients with PTSD from childhood trauma. The primary outcome was reduction of PTSD symptoms (clinician-administered PTSD Scale for DSM-5, CAPS-5) assessed at eight-week follow-up and a secondary outcome was self-report PTSD symptoms (Impact of Event Scale, IES-R). MDD was not a predictor of treatment outcome but did have a significant moderator effect. Patients with MDD showed a better outcome if they were treated with IR, whereas patients without MDD improved more in the EMDR condition. No impact of AD emerged. It seems essential to consider comorbid MDD when planning PTSD treatment to improve treatment outcomes. More research is needed to replicate our findings and focus on different kinds of PTSD treatments and other comorbidities.